Schedule 13D
-------------------------------------------
OMB APPROVAL
-------------------------------------------
OMB Number:
Expires:
Estimated average burden
hours per form...................
-------------------------------------------
UNITED STAES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. N/A)*
ImmunoPrecise Antibodies Ltd.
--------------------------------------------------------------------------------
(Name of Issuer)
Common
--------------------------------------------------------------------------------
(Title of Class of Securities)
45257F200
--------------------------------------------------------------------------------
(CUSIP Number)
Christian C. Park
Ingalls & Snyder, LLC
1325 Avenue of the Americas
New York, NY 10019
(212) 269-7894
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
June 29, 2023
--------------------------------------------------------------------------------
(Date of Event which Requires Filing
of this Statement)
If the filing person has previously filed a statement of Schedule 13G to report
the acquisition which is the subject of the Schedule 13D, and is filing this
schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box [ ].
*The remainder of this cover page shall be filed out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
(Continued on following page(s))
CUSIP No. 45257F200 13D
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Ingalls & Snyder, LLC
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ X]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
OO
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
New York
--------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES 0
BENEFICIALLY --------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH 0
REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
1,053,186
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,053,186
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
[ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.22%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IA
--------------------------------------------------------------------------------
The Shares reported herein are not limited to, but include those of the
personal accounts of William McHale, an advisor representative of the
Reporting Person. All of the individuals are advisory clients of the
Reporting Person.
The following Items are amended and restated in their entirety:
Item 1. Security and Issuer
ImmunoPrecise Antibodies Ltd.
Common Stock (the "Shares")
3204 4464 Markham Street
Victoria, BC V8Z 7X8
Item 2. Identity and Background
(a)Ingalls & Snyder, LLC
The Reporting Person is a limited liability company organized under the
laws of the State of New York.
(b)Business address and principal office for the Reporting Person:
(c)Present principal occupation or employment and the name, principal
business and address where employment occurs.
(d) During the last five years,the Reporting Person has not
been convicted in a criminal proceeding (excluding traffic
violations or similar misdemeanors).
(e) During the last five years the Reporting Person was not a party
to a civil proceeding of a judicial or administrative body of competent
jurisdiction, and is not subject to a judgment, decree or final order
enjoining future violations of,or prohibiting or mandating activities
subject to, federalor state securities laws or finding any violation
with respect to such laws.
(f)Citizenship:
Item 3. Source and Amount of Funds or Other Consideration.
Personal funds of Reporting Persons' advisory clients.
Item 4. Purpose of Transaction
The Reporting Person along with other shareholders are collectively
proposing a change to the members of the issuers board of directors.
The views of the informal group will be expressed through written and
oral communications, and may result in a call for a shareholder
meeting on the issue.
While the Reporting Person is along under the filing threshold
requirement, it is electing to file this Schedule D as it is a
part of a group of shareholders who share a common goal of
effecting a change to the board members. There are no formal written
agreements with other shareholders to act as a group.
Item 5. Interest in Securities of the Issuer
(a) The Reporting Person is the beneficial owner of 1,053,186 shares
which is equivalent to 4.22% of the outstanding shares of the issuer
based on the total number of outstanding shares reported by the
issuer on its most recent Form 10-Q.
The Reporting Person has the sole power to dispose of or direct the
disposition of 0 shares, shared power to dispose of or direct the
disposition of 1,053,186 shares, and shared voting power of 1,053,186
shares.
(d) Not applicable.
(e)
Item 6.Contracts, Arrangements, Understandings or Relationships with Respect
to Securities of the Issuer.
None
Item 7. Material to be Filed as Exhibits.
None
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true,
complete and correct.
Date: July 7, 2023
/s/ Christian C. Park
Christian C. Park